A rare complication of intravesical early instillation of mitomycin C after TURBT
نویسندگان
چکیده
منابع مشابه
Intravesical Instillation of Mitomycin C: A Cause of Delayed Bladder Perforation?
We present a case of bladder perforation secondary to intravesical instillation of mitomycin C following transurethral resection of bladder tumour (TURBT) and the role of early detection leading to successful conservative management. We also review the key relevant literature.
متن کاملPulmonary toxicity after intraperitoneal mitomycin C: a case report of a rare complication of HIPEC
BACKGROUND Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has become a common treatment approach for disseminated appendiceal neoplasms. Systemic absorption of intraperitoneal chemotherapeutics may lead to drug-induced toxicity, most commonly neutropenia. Mitomycin C has been the most commonly used chemotherapeutic in HIPEC for the past several decades...
متن کامل[Anti-tumor effect of intravesical instillation of mitomycin C combined with cytosine arabinoside].
The anti-tumor effect of twice a week instillation of 30 mg mitomycin C combined with 200 mg cytosine arabinoside dissolved in 30 ml saline was studied in 37 bladder tumor patients. Endoscopic or histological disappearance of the tumor was observed in 19 cases, average instillation being 16.4 times. Small (less than 1 cm in diameter), low grade, low stage and villous-surfaced tumors were more s...
متن کاملBCGitis: A rare complication after intravesical BCG therapy
In most cases, bladder carcinoma is located superficially, and the therapeutic approach is usually transurethral resection followed by intravesical therapy (chemotherapy or immunotherapy).(1,2) Initially produced as a vaccine against tuberculosis, BCG—an attenuated strain of Mycobacterium bovis—has been widely used in immunotherapy over the last decades.(1,3) Although BCG, used as immunotherapy...
متن کاملTherapies in bladder cancer: intravesical mitomycin-C
The use of intravesical therapy for the treatment of superficial bladder cancer aims to reduce morbidity and mortality by eradicating existing disease, preventing tumor recurrence and attempting to halt tumor progression. Mitomycin-C is a commonly used intravesical treatment option for superficial bladder cancer and was used for the first time by Shida and colleagues in 1967 [1]. It is an antit...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Urology Case Reports
سال: 2019
ISSN: 2214-4420
DOI: 10.1016/j.eucr.2019.100955